{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T10:17:00Z","timestamp":1768126620673,"version":"3.49.0"},"reference-count":50,"publisher":"Akademiai Kiado Zrt.","issue":"51","license":[{"start":{"date-parts":[[2021,12,19]],"date-time":"2021-12-19T00:00:00Z","timestamp":1639872000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2021,12,19]]},"abstract":"<jats:p><jats:bold>\u00d6sszefoglal\u00f3.<\/jats:bold> Az 1970-es \u00e9vek el\u0151tt a nyel\u0151cs\u0151r\u00e1kok csup\u00e1n 1\u20133%-a\n                    volt adenocarcinoma. A 70-es \u00e9vek k\u00f6zep\u00e9t\u0151l a nyel\u0151cs\u0151-adenocarcinoma mutatta a\n                    legnagyobb n\u00f6veked\u00e9st az \u00f6sszes malignus daganat k\u00f6z\u00fcl, \u00e9s a 90-es \u00e9vek\n                    k\u00f6zep\u00e9t\u0151l m\u00e1r meghaladta a laph\u00e1mr\u00e1kok el\u0151fordul\u00e1si gyakoris\u00e1g\u00e1t a nyugati\n                    vil\u00e1gban. Ma a nyel\u0151cs\u0151-adenocarcinoma relat\u00edv incidenci\u00e1ja Magyarorsz\u00e1gon\n                    34,7%, m\u00edg a nyugati vil\u00e1gban m\u00e1r 60% k\u00f6r\u00fcl van. A nyel\u0151cs\u0151-adenocarcinoma\n                    etiol\u00f3gi\u00e1j\u00e1ban meghat\u00e1roztak n\u00e9h\u00e1ny kock\u00e1zati t\u00e9nyez\u0151t, \u00edgy a\n                    gastrooesophagealis refluxot, a Barrett-nyel\u0151cs\u00f6vet, a k\u00f3ros k\u00f6v\u00e9rs\u00e9get, a\n                    doh\u00e1nyz\u00e1st \u00e9s a cs\u00f6kken\u0151 <jats:italic>Helicobacter pylori<\/jats:italic> fert\u0151z\u00f6tts\u00e9get.\n                    Ezek a t\u00e9nyez\u0151k azonban jelen voltak m\u00e1r a 70-es \u00e9vek el\u0151tt is. A k\u00f6v\u00e9rs\u00e9g\n                    el\u0151fordul\u00e1s\u00e1nak gyakoris\u00e1ga \u00e9s a k\u00f6vetkezm\u00e9nyes gastrooesophagealis reflux\n                    megdupl\u00e1z\u00f3dott az elm\u00falt 40 \u00e9vben, de ez egyed\u00fcl nem magyar\u00e1zza az\n                    adenocarcinom\u00e1k szaporod\u00e1s\u00e1nak \u00fctem\u00e9t. Egy \u00faj, hat\u00e9kony savcs\u00f6kkent\u0151\n                    gy\u00f3gyszercsoportnak, a H2-receptor-blokkol\u00f3knak a bevezet\u00e9s\u00e9re 1976-ban ker\u00fclt\n                    sor, \u00e9s ez egybeesik a szokatlanul nagy incidencian\u00f6veked\u00e9ssel. Tom DeMeester\n                    te\u00f3ri\u00e1ja szerint a savcs\u00f6kkent\u0151 kezel\u00e9s \u00e1ltal l\u00e9trehozott pH-v\u00e1ltoz\u00e1s okozhatja\n                    a reflux\u00e1tum carcinogenitas\u00e1nak fokoz\u00f3d\u00e1s\u00e1t. A Barrett-oesophagus \u00e9s a\n                    nyel\u0151cs\u0151-adenocarcinoma etiol\u00f3gi\u00e1j\u00e1ban, megel\u0151z\u00e9s\u00e9ben \u00e9s kezel\u00e9s\u00e9ben sz\u00e1mos\n                    ellentmond\u00e1s \u00e9s vit\u00e1s k\u00e9rd\u00e9s tapasztalhat\u00f3, k\u00fcl\u00f6n\u00f6sen a protonpumpag\u00e1tl\u00f3\n                    gy\u00f3gyszerek (PPI-k) hossz\u00fa t\u00e1v\u00fa haszn\u00e1lata k\u00f6r\u00fcl. A PPI-k hat\u00e1soss\u00e1ga a\n                    gy\u00f3gyszer t\u00falzott alkalmaz\u00e1s\u00e1hoz vezetett nem mindig megfelel\u0151 indik\u00e1ci\u00f3ban,\n                    kit\u00e9ve a betegeket potenci\u00e1lis kock\u00e1zatoknak. \u00d6sszefoglalva, a\n                    nyel\u0151cs\u0151-adenocarcinoma dr\u00e1mai n\u00f6veked\u00e9s\u00e9ben biztosan szerepet j\u00e1tszik az\n                    elh\u00edz\u00e1s \u00e9s a refluxbetegs\u00e9g ezzel p\u00e1rhuzamos terjed\u00e9se. Fontos tov\u00e1bb\u00e1 a\n                        <jats:italic>H. pylori<\/jats:italic> fert\u0151z\u00f6tts\u00e9g cs\u00f6kken\u00e9se, \u00e9s \u00faj szempont a hat\u00e1sos\n                    savcs\u00f6kkent\u0151 szerek sz\u00e9les k\u00f6r\u0171 alkalmaz\u00e1sa, melyek a reflux\u00e1tumban okozott\n                    pH-v\u00e1ltoz\u00e1ssal er\u0151s\u00edthetik a carcinogenesist. Orv Hetil. 2021; 162(51):\n                    2040\u20132046.<\/jats:p>\n                <jats:p><jats:bold>Summary.<\/jats:bold> Before the 1970s, only 1\u20133% of esophageal cancers were\n                    adenocarcinoma. Since the mid-70s, the incidence of esophageal adenocarcinoma\n                    has shown the greatest increase compared to all other cancer types and overtook\n                    squamous carcinoma incidence in the mid-90s in the Western countries. Today, the\n                    relative incidence of esophageal adenocarcinoma in Hungary is 34.7% and around\n                    60% in the Western countries. Some risk factors for esophageal adenocarcinoma\n                    have been identified such as gastroesophageal reflux disease, Barrett\u2019s\n                    esophagus, obesity, smoking and decreased prevalence of <jats:italic>Helicobacter\n                        pylori<\/jats:italic> infection, but these risk factors were already present\n                    before the 70s. The prevalence of obesity and the consequentially developed\n                    gastroesophageal reflux has doubled during the last 40 years, but it does not\n                    explain alone the dramatic rise in the esophageal adenocarcinoma incidence. The\n                    H2 blockers, as new effective antisecretory medication, were introduced in 1976,\n                    coinciding in time with the substantial rise of esophageal adenocarcinoma.\n                    According to the DeMeester theory, the change in the pH of gastric refluxate\n                    caused by acid suppression enhances its carcinogenic potential. There are a lot\n                    of controversies among the prevention, etiology and treatment of Barrett\u2019s\n                    esophagus and esophageal adenocarcinoma, especially regarding the long-term use\n                    of proton pump inhibitors (PPIs), an even more effective group of acid\n                    suppressors. The effectiveness of PPIs has led to an overuse exceeding its\n                    regular indications with little benefit, exposing patients to a number of\n                    potential risks. In conclusion, in the dramatic rise of the esophageal\n                    adenocarcinoma incidence, obesity accompanied by reflux disease and the\n                    decreased incidence of <jats:italic>H. pylori<\/jats:italic> infection certainly play\n                    important roles. The introduction of modern antisecretory drugs in the treatment\n                    of acid-related diseases promoting carcinogenesis, arises as a new\n                    consideration. Orv Hetil. 2021; 162(51): 2040\u20132046.<\/jats:p>","DOI":"10.1556\/650.2021.32354","type":"journal-article","created":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T14:00:48Z","timestamp":1641564048000},"page":"2040-2046","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.1","source":"Crossref","is-referenced-by-count":4,"title":["Nyel\u0151cs\u0151-adenocarcinoma."],"prefix":"10.1556","volume":"162","author":[{"given":"\u00d6rs P\u00e9ter","family":"Horv\u00e1th","sequence":"first","affiliation":[{"name":"P\u00e9csi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Janus Pannonius Klinikai K\u00f6zpont, Seb\u00e9szeti Klinika P\u00e9cs, Ifj\u00fas\u00e1g \u00fatja 13., 7624"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e1s","family":"Vereczkei","sequence":"additional","affiliation":[{"name":"P\u00e9csi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Janus Pannonius Klinikai K\u00f6zpont, Seb\u00e9szeti Klinika P\u00e9cs, Ifj\u00fas\u00e1g \u00fatja 13., 7624"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"ref0","unstructured":"1 K\u00e1sler M. (ed.) Basics of oncology. [Az onkol\u00f3gia alapjai.] Medicina K\u00f6nyvkiad\u00f3, Budapest, 2018. [Hungarian]"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/bjd.12335","article-title":"Long-term hazards of neonatal blue-light phototherapy","volume":"169","author":"2 Ol\u00e1h","year":"2013","unstructured":"2 Ol\u00e1h J, T\u00f3th-Moln\u00e1r E, Kem\u00e9ny L, et al. Long-term hazards of neonatal blue-light phototherapy. Br J Dermatol. 2013; 169: 243-249.","journal-title":"Br J Dermatol"},{"key":"ref2","unstructured":"3 Horv\u00e1th \u00d6P, Vereczkei A, Nagy T, et al. Gastric cancer. In: K\u00e1sler M. (ed.) Basics of oncology. [Gyomorr\u00e1k. In: K\u00e1sler M. (szerk.) Az onkol\u00f3gia alapjai.] Medicina K\u00f6nyvkiad\u00f3, Budapest, 2018; pp. 459-480. [Hungarian]"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0889-8553(05)70308-3","article-title":"Epidemiology of columnar-lined esophagus and adenocarcinoma","volume":"26","author":"4 Cameron","year":"1997","unstructured":"4 Cameron AJ. Epidemiology of columnar-lined esophagus and adenocarcinoma. Gastroenterol Clin North Am. 1997; 26: 487-494.","journal-title":"Gastroenterol Clin North Am"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5 Haggitt RC. Adenocarcinoma in Barrett's esophagus, a new epidemic? Hum Pathol. 1992; 23: 475-476.","DOI":"10.1016\/0046-8177(92)90121-I"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1111\/1759-7714.13311","article-title":"Trends in the incidence and survival of patients with esophageal cancer: a SEER database analysis","volume":"11","author":"6 He","year":"2020","unstructured":"6 He H, Chen N, Hou Y, et al. Trends in the incidence and survival of patients with esophageal cancer: a SEER database analysis. Thorac Cancer 2020; 11: 1121-1128.","journal-title":"Thorac Cancer"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"541794","DOI":"10.3389\/fonc.2020.541794","article-title":"The esophageal adenocarcinoma epidemic has reached Hungary: a multicenter, cross-sectional study","volume":"10","author":"7 Tinusz","year":"2020","unstructured":"7 Tinusz B, Szap\u00e1ry LB, Pal\u00e1di B, et al. The esophageal adenocarcinoma epidemic has reached Hungary: a multicenter, cross-sectional study. Front Oncol. 2020; 10: 541794.","journal-title":"Front Oncol"},{"key":"ref7","unstructured":"8 Horvath \u00d6P, Csan\u00e1di J, Cs\u00edkos M, et al. Surgery for esophageal cancer, long term survival, factors influencing survival. [Nyel\u0151cs\u0151r\u00e1k miatt resec\u00e1lt betegek hossz\u00fa t\u00e1v\u00fa t\u00fal\u00e9l\u00e9se \u00e9s a t\u00fal\u00e9l\u00e9st befoly\u00e1sol\u00f3 t\u00e9nyez\u0151k.] Magy Seb. 1985; 38: 10-19. [Hungarian]"},{"key":"ref8","unstructured":"9 Horv\u00e1th \u00d6P, Petri I, Csan\u00e1di J, et al. Two complications in endobrachyesophagus. [Az endobrachyesophagusr\u00f3l k\u00e9t sz\u00f6v\u0151dm\u00e9nnyel t\u00e1rsult eset kapcs\u00e1n.] Magy Seb. 1982; 35: 169-174. [Hungarian]"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1136\/gutjnl-2016-313589","article-title":"Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis","volume":"67","author":"10 Eusebi","year":"2018","unstructured":"10 Eusebi LH, Ratnakumaran R, Yuan Y. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut 2018; 67: 430-440.","journal-title":"Gut"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1053\/j.gastro.2017.07.045","article-title":"Presentation and epidemiology of gastroesophageal reflux disease","volume":"154","author":"Richter JE","year":"2018","unstructured":"11 Richter JE, Rubenstein JH. Presentation and epidemiology of gastroesophageal reflux disease. Gastroenterology 2018; 154: 267-276.","journal-title":"Gastroenterology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.3748\/wjg.v24.i28.3071","article-title":"Helicobacter pylori in human health and disease: mechanisms for local gastric and systemic effects","volume":"24","author":"12 Bravo","year":"2018","unstructured":"12 Bravo D, Hoare A, Soto C. Helicobacter pylori in human health and disease: mechanisms for local gastric and systemic effects. World J Gastroenterol. 2018; 24: 3071-3089.","journal-title":"World J Gastroenterol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1111\/j.1365-2036.2007.03326.x","article-title":"Influence of genetics on irritable bowel syndrome, gastro-oesophageal reflux and dyspepsia: a twin study","volume":"25","author":"13 Lembo","year":"2007","unstructured":"13 Lembo A, Zaman M, Jones M, et al. Influence of genetics on irritable bowel syndrome, gastro-oesophageal reflux and dyspepsia: a twin study. Aliment Pharmacol Ther. 2007; 25: 1343-1350.","journal-title":"Aliment Pharmacol Ther"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1007\/s10620-016-4155-9","article-title":"Potential role of the microbiome in Barrett's esophagus and esophageal adenocarcinoma","volume":"61","author":"14 Snider","year":"2016","unstructured":"14 Snider EJ, Freedberg DE, Abrams JA. Potential role of the microbiome in Barrett's esophagus and esophageal adenocarcinoma. Dig Dis Sci. 2016; 61: 2217-2225.","journal-title":"Dig Dis Sci"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1002\/cncr.30365","article-title":"Metabolic syndrome and risk of esophageal adenocarcinoma in elderly patients in the United States: an analysis of SEER-Medicare data","volume":"123","author":"15 Drahos","year":"2017","unstructured":"15 Drahos J, Ricker W, Pfeiffer RM, et al. Metabolic syndrome and risk of esophageal adenocarcinoma in elderly patients in the United States: an analysis of SEER-Medicare data. Cancer 2017; 123: 657-665.","journal-title":"Cancer"},{"key":"ref15","unstructured":"16 Chandrasoma PT, DeMeester TR. GERD: reflux to esophageal adenocarcinoma. Elsevier, Amsterdam, 2010."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1007\/s10620-008-0413-9","article-title":"The association between obesity and GERD: a review of the epidemiological evidence","volume":"53","author":"17 El-Serag","year":"2008","unstructured":"17 El-Serag H. The association between obesity and GERD: a review of the epidemiological evidence. Dig Dis Sci. 2008; 53: 2307-2312.","journal-title":"Dig Dis Sci"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/archsurg.136.11.1267","article-title":"Predictive factors of Barrett esophagus: multivariate analysis of 502 patients with gastroesophageal reflux disease","volume":"136","author":"18 Campos","year":"2001","unstructured":"18 Campos GM, DeMeester SR, Peters JH, et al. Predictive factors of Barrett esophagus: multivariate analysis of 502 patients with gastroesophageal reflux disease. Arch Surg. 2001; 136: 1267-1273.","journal-title":"Arch Surg"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1097\/SLA.0000000000001207","article-title":"Rat reflux model of esophageal cancer and its implication in human disease","volume":"262","author":"19 Greene","year":"2015","unstructured":"19 Greene CL, Worrell SG, DeMeester TR. Rat reflux model of esophageal cancer and its implication in human disease. Ann Surg. 2015; 262: 910-924.","journal-title":"Ann Surg"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20 Spechler SJ. Does Barrett's esophagus regress after surgery (or proton pump inhibitors)? Dig Dis. 2014; 32: 156-163.","DOI":"10.1159\/000357184"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21 Hu Q, Sun TT, Hong J. Proton pump inhibitors do not reduce the risk of esophageal adenocarcinoma in patients with Barrett's esophagus: a systematic review and meta-analysis. PLoS ONE 2017; 12: e0169691.","DOI":"10.1371\/journal.pone.0169691"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/S1072-7515(03)00147-9","article-title":"Barrett's esophagus can and does regress after antireflux surgery: a study of prevalence and predictive features","volume":"196","author":"22 Gurski","year":"2003","unstructured":"22 Gurski RR, Peters JH, Hagen JA, et al. Barrett's esophagus can and does regress after antireflux surgery: a study of prevalence and predictive features. J Am Coll Surg. 2003; 196: 706-713.","journal-title":"J Am Coll Surg"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/01.sla.0000150072.55037.e3","article-title":"The mutagenic potential of duodenoesophageal reflux","volume":"241","author":"23 Theisen","year":"2005","unstructured":"23 Theisen J, Peters JH, Fein M, et al. The mutagenic potential of duodenoesophageal reflux. Ann Surg. 2005; 241: 63-68.","journal-title":"Ann Surg"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1146\/annurev.med.50.1.469","article-title":"Biology of gastroesophageal reflux disease: pathophysiology relating to medical and surgical treatment","volume":"50","author":"24 DeMeester","year":"1999","unstructured":"24 DeMeester TR, Peters JH, Bremner CG, et al. Biology of gastroesophageal reflux disease: pathophysiology relating to medical and surgical treatment. Annu Rev Med. 1999; 50: 469-506.","journal-title":"Annu Rev Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s00428-005-0045-9","article-title":"Claudin expression in Barrett's esophagus and adenocarcinoma","volume":"447","author":"25 Gy\u0151rffy","year":"2005","unstructured":"25 Gy\u0151rffy H, Holczbauer A, Nagy P, et al. Claudin expression in Barrett's esophagus and adenocarcinoma. Virchows Arch. 2005; 447: 961-968.","journal-title":"Virchows Arch"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00535-009-0082-2","article-title":"Differential gene expression in normal esophagus and Barrett's esophagus","volume":"44","author":"26 Wang","year":"2009","unstructured":"26 Wang J, Qin R, Ma Y, et al. Differential gene expression in normal esophagus and Barrett's esophagus. J Gastroenterol. 2009; 44: 897-911.","journal-title":"J Gastroenterol"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27 Mitre MC, Katzka DA, Brensinger CM, et al. Schatzki ring and Barrett's esophagus: do they occur together? Dig Dis Sci. 2004; 49: 770-773.","DOI":"10.1023\/B:DDAS.0000030087.07078.8a"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1007\/s10620-018-5184-3","article-title":"Gastroesophageal reflux disease might induce certain - supposedly adaptive - changes in the esophagus: a hypothesis","volume":"63","author":"28 Bogn\u00e1r","year":"2018","unstructured":"28 Bogn\u00e1r L, Vereczkei A, Papp A, et al. Gastroesophageal reflux disease might induce certain - supposedly adaptive - changes in the esophagus: a hypothesis. Dig Dis Sci. 2018; 63: 2529-2535.","journal-title":"Dig Dis Sci"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1053\/j.gastro.2017.04.047","article-title":"Complications of proton pump inhibitor therapy","volume":"153","author":"29 Vaezi","year":"2017","unstructured":"29 Vaezi MF, Yang YX, Howden CW. Complications of proton pump inhibitor therapy. Gastroenterology 2017; 153: 35-48.","journal-title":"Gastroenterology"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S1091-255X(98)80072-3","article-title":"Bile reflux in benign and malignant Barrett's esophagus: effect of medical acid suppression and Nissen fundoplication","volume":"2","author":"30 Stein","year":"1998","unstructured":"30 Stein HJ, Kauer WK, Feussner H, et al. Bile reflux in benign and malignant Barrett's esophagus: effect of medical acid suppression and Nissen fundoplication. J Gastrointest Surg. 1998; 2: 333-341.","journal-title":"J Gastrointest Surg"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/j.mehy.2006.10.026","article-title":"Glycine conjugated and free bile acids, aided by acid suppression, can easily enter the esophageal epithelium where they can activate oncogenes and eventually carcinogenesis","volume":"68","author":"31 Stamp","year":"2007","unstructured":"31 Stamp D. Glycine conjugated and free bile acids, aided by acid suppression, can easily enter the esophageal epithelium where they can activate oncogenes and eventually carcinogenesis. Med Hypotheses 2007; 68: 1428-1429.","journal-title":"Med Hypotheses"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1002\/lary.28051","article-title":"Esophageal pepsin and proton pump synthesis in Barrett's esophagus and esophageal adenocarcinoma","volume":"129","author":"32 Samuels","year":"2019","unstructured":"32 Samuels TL, Altman KW, Gould JC, et al. Esophageal pepsin and proton pump synthesis in Barrett's esophagus and esophageal adenocarcinoma. Laryngoscope 2019; 129: 2687-2695.","journal-title":"Laryngoscope"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/ajg.2012.387","article-title":"Risk factors in the development of esophageal adenocarcinoma","volume":"108","author":"33 Pohl","year":"2013","unstructured":"33 Pohl H, Wrobel K, Bojarski C, et al. Risk factors in the development of esophageal adenocarcinoma. Am J Gastroenterol. 2013; 108: 200-207.","journal-title":"Am J Gastroenterol"},{"key":"ref33","unstructured":"34 Hersz\u00e9nyi L. One million a month - there are times when many, there are times when there is little. [Havi egy milli\u00f3 - van amikor sok, van amikor kev\u00e9s.] Gasztroenterol Hepatol Szle. 2019; 5: 174-175. [Hungarian]"},{"key":"ref34","unstructured":"35 Bajor J. Meaningful antisecretory therapy. [\u00c9szszer\u0171 savcs\u00f6kkent\u0151 ter\u00e1pia.] Gasztroenterol Hepatol Szle. 2020; 6: 163-166. [Hungarian]"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1038\/s41395-018-0070-3","article-title":"Helicobacter pylori infection is associated with reduced risk of Barrett's esophagus: an analysis of the Barrett's and esophageal adenocarcinoma consortium","volume":"113","author":"36 Wang","year":"2018","unstructured":"36 Wang Z, Shaheen NJ, Whiteman D, et al. Helicobacter pylori infection is associated with reduced risk of Barrett's esophagus: an analysis of the Barrett's and esophageal adenocarcinoma consortium. Am J Gastroenterol. 2018; 113: 1148-1155.","journal-title":"Am J Gastroenterol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1001\/jama.2013.226450","article-title":"Barrett esophagus and risk of esophageal cancer: a clinical review","volume":"310","author":"37 Spechler","year":"2013","unstructured":"37 Spechler SJ. Barrett esophagus and risk of esophageal cancer: a clinical review. JAMA 2013; 310: 627-636.","journal-title":"JAMA"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S1091-255X(00)80032-3","article-title":"Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids","volume":"4","author":"38 Theisen","year":"2000","unstructured":"38 Theisen J, Nehra D, Citron D, et al. Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids. Gastrointest Surg. 2000; 4: 50-54.","journal-title":"Gastrointest Surg"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.canep.2018.02.004","article-title":"Maintenance proton pump inhibition therapy and risk of oesophageal cancer","volume":"53","author":"39 Brusselaers","year":"2018","unstructured":"39 Brusselaers N, Engstrand L, Lagergren J. Maintenance proton pump inhibition therapy and risk of oesophageal cancer. Cancer Epidemiol. 2018; 53: 172-177.","journal-title":"Cancer Epidemiol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/S0140-6736(94)90349-2","article-title":"Prevalence of metaplasia at the gastro-esophageal junction","volume":"344","author":"40 Spechler","year":"1994","unstructured":"40 Spechler SJ, Zeroogian JM, Antonioli DA, et al. Prevalence of metaplasia at the gastro-esophageal junction. Lancet 1994; 344: 1533-1536.","journal-title":"Lancet"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/NEJM199903183401101","article-title":"Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma","volume":"340","author":"41 Lagergren","year":"1999","unstructured":"41 Lagergren J, Bergst\u00f6m R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999; 340: 825-831.","journal-title":"N Engl J Med"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"42 Horv\u00e1th \u00d6P, Varga G, Bir\u00f3 Zs, et al. Complications and reoperations following laparoscopic antireflux surgery. [Sz\u00f6v\u0151dm\u00e9nyek \u00e9s reoper\u00e1ci\u00f3k laparoszk\u00f3pos antireflux m\u0171t\u00e9tek ut\u00e1n.] Magy Seb. 2016; 69: 91-99. [Hungarian]","DOI":"10.1556\/1046.69.2016.3.1"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1056\/NEJMoa054391","article-title":"Body-mass index and symptoms of gastroesophageal reflux in women","volume":"354","author":"43 Jacobson","year":"2006","unstructured":"43 Jacobson BC, Somers SC, Fuchs CS, et al. Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med. 2006; 354: 2340-2348.","journal-title":"N Engl J Med"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"44 Vereczkei A, Horvath \u00d6P, Varga G, et al. Gastroesophageal reflux disease and non-small cell lung cancer. Results of a pilot study. Dis Esophagus 2008; 21: 457-460.","DOI":"10.1111\/j.1442-2050.2007.00796.x"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"815","DOI":"10.3748\/wjg.v21.i3.815","article-title":"Gastroesophageal reflux disease and non-esophageal cancer","volume":"21","author":"45 Herbella","year":"2015","unstructured":"45 Herbella FA, Neto SP, Santoro IL, et al. Gastroesophageal reflux disease and non-esophageal cancer. World J Gastroenterol. 2015; 21: 815-819.","journal-title":"World J Gastroenterol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.3390\/cancers11081174","article-title":"Use of antibiotics and risk of cancer: a systematic review and meta-analysis of observational studies","volume":"11","author":"46 Petrelli","year":"2019","unstructured":"46 Petrelli F, Ghidini M, Ghidini A, et al. Use of antibiotics and risk of cancer: a systematic review and meta-analysis of observational studies. Cancers (Basel) 2019; 11: 1174.","journal-title":"Cancers (Basel)"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.gtc.2015.02.010","article-title":"The effect of proton pump inhibitors on Barrett's esophagus","volume":"44","author":"47 Dunbar","year":"2015","unstructured":"47 Dunbar KB, Souza RF, Spechler SJ. The effect of proton pump inhibitors on Barrett's esophagus. Gastroenterol Clin North Am. 2015; 44: 415-424.","journal-title":"Gastroenterol Clin North Am"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.gassur.2004.08.001","article-title":"Omeprazole does not reduce gastroesophageal reflux: new insights using multichannel intraluminal impedance technology","volume":"8","author":"48 Tamhankar","year":"2004","unstructured":"48 Tamhankar AP, Peters JH, Portale G, et al. Omeprazole does not reduce gastroesophageal reflux: new insights using multichannel intraluminal impedance technology. J Gastrointest Surg. 2004; 8: 890-897.","journal-title":"J Gastrointest Surg"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.dld.2012.12.020","article-title":"Epidemiology and risk factors for oesophageal adenocarcinoma","volume":"45","author":"49 Lepage","year":"2013","unstructured":"49 Lepage C, Drouillard A, Jouve JL, et al. Epidemiology and risk factors for oesophageal adenocarcinoma. Dig Liver Dis. 2013; 45: 625-629.","journal-title":"Dig Liver Dis"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1053\/j.gastro.2017.07.046","article-title":"The epidemiology of esophageal adenocarcinoma","volume":"154","author":"50 Coleman","year":"2018","unstructured":"50 Coleman HG, Xie SH, Lagergren J. The epidemiology of esophageal adenocarcinoma. Gastroenterology 2018; 154: 390-405.","journal-title":"Gastroenterology"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/162\/51\/article-p2040.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/162\/51\/article-p2040.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/162\/51\/article-p2040.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T11:34:04Z","timestamp":1698406444000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/162\/51\/article-p2040.xml"}},"subtitle":["Mi lehet az oka az incidencia jelent\u0151s\n                    n\u00f6veked\u00e9s\u00e9nek?"],"short-title":[],"issued":{"date-parts":[[2021,12,19]]},"references-count":50,"journal-issue":{"issue":"51"},"URL":"https:\/\/doi.org\/10.1556\/650.2021.32354","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,19]]}}}